Castlight Health Announces Third Quarter 2015 Results SAN

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Castlight Health Announces Third Quarter 2015 Results

SAN FRANCISCO, CA --(Marketwired - November 04, 2015) - Castlight Health, Inc. ( NYSE : CSLT ), the leader in enterprise healthcare management (EHM), today announced results for its third quarter ended September 30, 2015.

"Among the new customers Castlight added during the quarter were four Fortune 500 businesses. We also signed an exciting collaboration with Anthem Inc. to accelerate adoption of Castlight technologies," said Giovanni Colella, M.D., co-founder and chief executive officer of Castlight Health. "We significantly expanded our product leadership with the addition of Castlight Action, a new product that gives benefits leaders simple and effective new ways to proactively identify and connect employees who need care with the benefits that can help them."

Financial Performance for the Three Months Ended September 30, 2015

  • Total revenue for the third quarter of 2015 was $19.5 million, an increase of 60% from the third quarter of 2014. Subscription revenue was $18.2 million, an increase of 62% on a year-over-year basis.
  • Gross margin for the third quarter of 2015 was 55.5%, compared to a gross margin of 41.4% in the third quarter of 2014. Non-GAAP gross margin for the third quarter of 2015 was 59.3% compared to a non-GAAP gross margin of 44.4% in the third quarter of 2014.
  • Operating loss for the third quarter of 2015 was $20.1 million, compared to an operating loss of $20.3 million in the third quarter of 2014. Non-GAAP operating loss for the third quarter of 2015 was $15.9 million, compared to a non-GAAP operating loss of $16.2 million in the third quarter of 2014.
  • Net loss per basic and diluted share was $0.21 in the third quarter of 2015, compared to a net loss per basic and diluted share of $0.23 in the third quarter of 2014. The non-GAAP net loss per basic and diluted share for the third quarter of 2015 was $0.17, compared to a net loss per basic and diluted share of $0.18 in the third quarter of 2014. For both GAAP and non-GAAP purposes, the weighted average basic and diluted share count for the third quarter of 2015 was 94.4 million compared to 89.7 million in the third quarter of 2014.
  • Total cash, cash equivalents and marketable securities were $147.2 million at the end of the third quarter of 2015. Cash used in operations for the third quarter of 2015 was $14.5 million, compared to $7.5 million used in operations in the third quarter of 2014.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures".

Business Outlook

Q4 2015 Guidance : Revenue for the company's fourth quarter is expected to be $20.7 million to $21.0 million. We expect to generate a non-GAAP operating loss in the range of $15.4 million to $16.4 million and a non-GAAP net loss per share of $0.16 to $0.17 based on 95 million weighted average basic and diluted shares outstanding.

Full Year 2015 Guidance: Revenue for the company's full year 2015 is expected to be in the range of $74.7 million to $75.0 million, an increase of 64% year-over-year. Non-GAAP operating loss is expected to be in the range of $65.0 million to $66.0 million. Non-GAAP basic and diluted loss per share is expected to be in the range of $0.68 to $0.70 based on 94 million to 95 million weighted average basic and diluted common shares outstanding.

For both the fourth quarter and the full year 2015, non-GAAP guidance excludes the effects of stock-based compensation expense and capitalization and amortization of internal-use software.

Quarterly Conference Call

Castlight Health will host a conference call to discuss its third quarter 2015 results today at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the company's Investor Relations website at http://ir.castlighthealth.com . In addition, an archive of the webcast can be accessed through the same link. Participants who choose to call in to the conference call can do so by dialing 1-877-201-0168. The conference ID number is 57888376. A replay will be available for one week at 1-855-859-2056, passcode 57897700.

About Castlight Health

Castlight Health, Inc. ( NYSE : CSLT ) is a leader in Enterprise Healthcare Management. We believe great healthcare builds great business and U.S. enterprises can gain control over the $620 billion spent annually on healthcare, transforming a crippling cost into a strategic business advantage. Recognized as a top 2014 software platform by the HR Technology Conference & Exposition, the Castlight Enterprise Healthcare Cloud enables employers to understand and manage all their healthcare investments while helping employees make the best possible healthcare decisions. Castlight is a great place to work, honored with a Glassdoor Employees' Choice award and recognized by Rock Health for Diversity in Leadership . For more information visit www.castlighthealth.com . Follow us on Twitter and LinkedIn and Like us on Facebook . Source: Castlight Health.

Non-GAAP Financial Measures

To supplement Castlight Health's financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross margin (loss), non-GAAP operating expense, non-GAAP operating loss, non-GAAP net loss and non-GAAP net loss per share. These non-GAAP financial measures differ from GAAP financial measures in that they exclude stock-based compensation, warrant expense, capitalization and amortization of internal-use software and the associated tax impact of these items, where applicable.

We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company's core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company's historical financial performance.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the fourth quarter of 2015 and full year 2015 to comparable GAAP operating loss and net loss per share guidance because we do not provide guidance for stock-based compensation expense and capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP operating loss. The factors that may impact our future stock-based compensation expense and capitalization and amortization of internal-use software are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort.

These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP. Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company's financial information in its entirety and not rely on a single financial measure.

Safe Harbor For Forward-Looking Statements

This press release contains forward-looking statements about Castlight Health's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health's fourth quarter and full year projections, our expectations for future performance of our business, market growth and business conditions, future innovation by the company and future developments with respect to the digital healthcare industry. Statements including words such as "anticipate," "believe," "estimate," "will," "continue," "expect," or "future," and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health's documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.

Copyright 2015 Castlight Health, Inc. Castlight Health ® is the registered trademark of Castlight Health, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.

CASTLIGHT HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

   
  As of
  September 30, 2015   December 31, 2014
  (unaudited)    
Assets      
Current assets:      
  Cash and cash equivalents $ 25,671     $ 17,425  
  Marketable securities   121,525       175,057  
  Accounts receivable, net   13,645       11,097  
  Deferred commissions   3,864       3,675  
  Prepaid expenses and other current assets   5,134       3,476  
Total current assets   169,839       210,730  
Property and equipment, net   6,269       3,630  
Marketable securities, noncurrent   -       6,220  
Restricted cash, noncurrent   1,000       -  
Deferred commissions, noncurrent   3,145       2,563  
Other assets   4,670       131  
Total assets $ 184,923     $ 223,274  
Liabilities and stockholders' equity          
Current liabilities:          
  Accounts payable $ 4,057     $ 3,217  
  Accrued expenses and other current liabilities   4,975       5,791  
  Accrued compensation   9,457       10,455  
  Deferred revenue   24,592       20,708  
Total current liabilities   43,081       40,171  
Deferred revenue, noncurrent   8,538       6,652  
Other liabilities, noncurrent   1,455       261  
Total liabilities   53,074       47,084  
Commitments and contingencies          
Stockholders' equity   131,849       176,190  
Total liabilities and stockholders' equity $ 184,923     $ 223,274  
               

CASTLIGHT HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(unaudited)

         
    Three Months Ended September 30,   Nine Months Ended September 30,
    2015   2014   2015   2014
Revenue:                
  Subscription   $ 18,233     $ 11,254     $ 50,417     $ 28,293  
  Professional services     1,306       955       3,583       2,825  
Total revenue     19,539       12,209       54,000       31,118  
Cost of revenue:                        
  Cost of subscription (1)     3,081       2,596       8,532       8,223  
  Cost of professional services (1)     5,606       4,559       15,581       12,932  
Total cost of revenue     8,687       7,155       24,113       21,155  
Gross profit     10,852       5,054       29,887       9,963  
Operating expenses:                        
  Sales and marketing (1)     16,731       14,760       50,835       46,267  
  Research and development (1)     7,868       5,630       21,853       16,633  
  General and administrative (1)     6,311       4,944       18,291       13,473  
Total operating expenses     30,910       25,334       90,979       76,373  
Operating loss     (20,058 )     (20,280 )     (61,092 )     (66,410 )
Other income, net     51       81       230       154  
Net loss   $ (20,007 )   $ (20,199 )   $ (60,862 )   $ (66,256 )
Net loss per share, basic and diluted   $ (0.21 )   $ (0.23 )   $ (0.65 )   $ (0.96 )
Weighted-average shares used to compute basic and diluted net loss per share     94,409       89,698       93,343       68,960  
                                 
1. Includes stock-based compensation expense as follows:
                                 
         
    Three Months Ended September 30,   Nine Months Ended September 30,
    2015   2014   2015   2014
Cost of revenue:                
  Cost of subscription   $ 96     $ 60     $ 196     $ 99  
  Cost of professional services     647       306       1,522       726  
Sales and marketing     2,058       2,013       5,883       4,339  
Research and development     981       561       2,344       1,475  
General and administrative     1,177       1,169       3,100       2,963  
                                 

CASTLIGHT HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(unaudited)

         
    Three Months Ended September 30,   Nine Months Ended September 30,
    2015   2014   2015   2014
Operating activities:                
Net loss   $ (20,007 )   $ (20,199 )   $ (60,862 )   $ (66,256 )
Adjustments to reconcile net loss to net cash used in operating activities:                        
  Depreciation     468       340       1,378       944  
  Stock-based compensation     4,959       4,109       13,045       9,602  
  Amortization of deferred commissions     917       875       2,576       3,119  
  Accretion and amortization of marketable securities     299       524       1,126       1,021  
  Expense related to warrant     -       160       -       2,659  
  Changes in operating assets and liabilities:                        
    Accounts receivable     (2,597 )     (886 )     (2,548 )     (6,213 )
    Deferred commissions     (1,595 )     (2,257 )     (3,346 )     (3,626 )
    Prepaid expenses and other assets     792       (245 )     (1,026 )     (1,922 )
    Accounts payable     (542 )     (191 )     716       193  
    Accrued expenses and other liabilities     1,429       3,956       (1,740 )     2,753  
    Deferred revenue     1,367       6,356       5,770       14,633  
Net cash used in operating activities     (14,510 )     (7,458 )     (44,911 )     (43,093 )
Investing activities:                        
  Restricted cash     -       -       (1,000 )     101  
  Investment in related party     (1,000 )     -       (4,125 )     -  
  Purchase of property and equipment     (1,806 )     (431 )     (3,499 )     (1,398 )
  Purchase of marketable securities     (67,366 )     (48,213 )     (86,324 )     (210,388 )
  Sales of marketable securities     -       -       5,000       13,000  
  Maturities of marketable securities     78,466       45,765       140,019       53,765  
Net cash provided by (used in) investing activities     8,294       (2,879 )     50,071       (144,920 )
Financing activities:                        
  Proceeds from the exercise of stock options     354       300       3,180       1,928  
  Payments of deferred financing costs     -       -       (94 )     -  
  Net proceeds from initial public offering     -       -       -       186,162  
Net cash provided by financing activities     354       300       3,086       188,090  
                         
Net increase (decrease) in cash and cash equivalents     (5,862 )     (10,037 )     8,246       77  
Cash and cash equivalents at beginning of period     31,533       35,268       17,425       25,154  
Cash and cash equivalents at end of period   $ 25,671     $ 25,231     $ 25,671     $ 25,231  
                                 

CASTLIGHT HEALTH, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(In thousands, except per share data)

(unaudited)

        Three Months Ended   Nine Months Ended
        September 30,   June 30,   September 30,   September 30,   September 30,
        2015   2015   2014   2015   2014
Gross profit:                    
  GAAP gross profit subscription   $ 15,152     $ 14,346     $ 8,658     $ 41,885     $ 20,070  
  GAAP gross margin subscription     83.1 %     83 %     76.9 %     83.1 %     70.9 %
    Stock-based compensation expense     96       67       60       196       99  
    Amortization of internal-use software     24       24       -       72       -  
  Non-GAAP gross profit subscription   $ 15,272     $ 14,437     $ 8,718     $ 42,153     $ 20,169  
  Non-GAAP gross margin subscription     83.8 %     83.6 %     77.5 %     83.6 %     71.3 %
  GAAP gross loss professional services   $ (4,300 )   $ (4,090 )   $ (3,604 )   $ (11,998 )   $ (10,107 )
  GAAP gross loss percentage professional services     (329 )%     (332 )%     (377 )%     (335 )%     (358 )%
    Stock-based compensation expense     647       450       306       1,522       726  
    Capitalization of internal-use software     (33 )     -       -       (33 )     -  
  Non-GAAP gross loss professional services   $ (3,686 )   $ (3,640 )   $ (3,298 )   $ (10,509 )   $ (9,381 )
  Non-GAAP gross loss percentage professional services     (282 )%     (295 )%     (345 )%     (293 )%     (332 )%
  GAAP gross profit   $ 10,852     $ 10,256     $ 5,054     $ 29,887     $ 9,963  
  GAAP gross margin     55.5 %     55.4 %     41.4 %     55.3 %     32.0 %
    Impact of non-GAAP adjustments     734       541       366       1,757       825  
  Non-GAAP gross profit   $ 11,586     $ 10,797     $ 5,420     $ 31,644     $ 10,788  
  Non-GAAP gross margin     59.3 %     58.3 %     44.4 %     58.6 %     34.7 %
Operating expense:                              
  GAAP sales and marketing   $ 16,731     $ 17,641     $ 14,760     $ 50,835     $ 46,267  
    Expense related to warrant     -       -       (160 )     -       (2,659 )
    Stock-based compensation expense     (2,058 )     (2,074 )     (2,013 )     (5,883 )     (4,339 )
  Non-GAAP sales and marketing   $ 14,673     $ 15,567     $ 12,587     $ 44,952     $ 39,269  
  GAAP research and development   $ 7,868     $ 7,391     $ 5,630     $ 21,853     $ 16,633  
    Stock-based compensation expense     (981 )     (730 )     (561 )     (2,344 )     (1,475 )
    Capitalization of internal-use software     841       513       162       1,636       162  
  Non-GAAP research and development   $ 7,728     $ 7,174     $ 5,231     $ 21,145     $ 15,320  
  GAAP general and administrative   $ 6,311     $ 6,517     $ 4,944     $ 18,291     $ 13,473  
    Stock-based compensation expense     (1,177 )     (896 )     (1,169 )     (3,100 )     (2,963 )
  Non-GAAP general and administrative   $ 5,134     $ 5,621     $ 3,775     $ 15,191     $ 10,510  
  GAAP operating expense   $ 30,910     $ 31,549     $ 25,334     $ 90,979     $ 76,373  
    Impact of non-GAAP adjustments     (3,375 )     (3,187 )     (3,741 )     (9,691 )     (11,274 )
  Non-GAAP operating expense   $ 27,535     $ 28,362     $ 21,593     $ 81,288     $ 65,099  
Operating loss:                              
  GAAP operating loss   $ (20,058 )   $ (21,293 )   $ (20,280 )   $ (61,092 )   $ (66,410 )
    Impact of non-GAAP adjustments     4,109       3,728       4,107       11,448       12,099  
  Non-GAAP operating loss   $ (15,949 )   $ (17,565 )   $ (16,173 )   $ (49,644 )   $ (54,311 )
Net loss and net loss per share:                              
  GAAP net loss   $ (20,007 )   $ (21,212 )   $ (20,199 )   $ (60,862 )   $ (66,256 )
    Total pre-tax impact of non-GAAP adjustments     4,109       3,728       4,107       11,448       12,099  
    Income tax impact of non-GAAP adjustments     -       -       -       -       -  
  Non-GAAP net loss   $ (15,898 )   $ (17,484 )   $ (16,092 )   $ (49,414 )   $ (54,157 )
  Basic and Diluted net loss per share                              
    GAAP   $ (0.21 )   $ (0.23 )   $ (0.23 )   $ (0.65 )   $ (0.96 )
    Non-GAAP   $ (0.17 )   $ (0.19 )   $ (0.18 )   $ (0.53 )   $ (0.79 )
  Shares used in basic and diluted net loss per share computation     94,409       93,804       89,698       93,343       68,960  

Investor Contact : Charles Butler ir@castlighthealth.com 415-829-1400 Media Contact : Jim Rivas press@castlighthealth.com 415-515-8780

Scroll down for more posts ▼

Top 10 Most Recent News Articles

QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 172

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 134

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 154

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 71

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 118

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Lyft Upgraded to Buy: Insights for Future Growth Potential

Updated Category News Views 292

Lyft's Upgrade by Benchmark: A Closer Look Benchmark analysts have recently upgraded Lyft (NASDAQ: LYFT) from Hold to Buy, highlighting what's described as "significant optionality" for the rideshare company. This decision comes despite the heightened competition from major players like Tesla and Waymo, indicating confidence in Lyft's capability to navigate potential...

Continue Reading
LiveOne Board Changes Amid Expansion and Financial Growth

Updated Category News Views 120

LiveOne Announces Departure of Board Member LiveOne, Inc. (NASDAQ:LVO) has recently made headlines in the retail-eating sector with the announcement of Craig Foster's resignation from its board of directors. Foster, who also contributed to the Audit Committee and Nominating and Corporate Governance Committee, stepped down to focus on his other professional commitments....

Continue Reading
Concorde International Group's Remarkable 80% After-Hours Surge

Updated Category News Views 429

Concorde International Group's Stock Surge Explained Concorde International Group Ltd. (NASDAQ: CIGL) has captured attention in the stock market after experiencing an impressive 80.16% increase during after-hours trading, reaching a price of $4.63. Investors are buzzing and speculating about what led to this dramatic leap. Exciting New Equity Incentive Plan Announced The...

Continue Reading
Celebrating the Legacy of Dr. Iain Douglas-Hamilton

Updated Category News Views 301

Special Screenings of A Life Among Elephants In a remarkable celebration of conservation, special screenings of the inspiring film A Life Among Elephants will honor the legacy of Dr. Iain Douglas-Hamilton. This film encapsulates the essence of his lifelong dedication to elephant conservation, portraying not only the threats faced by these majestic creatures but also the...

Continue Reading
Saudi Arabia Launches Major SME Report at Biban24 Event

Updated Category News Views 75

Saudi Arabia Presents Key Economic Insights at Biban24 As Saudi Arabia continues its path toward achieving ambitious Vision 2030 objectives, Monsha'at, the authority dedicated to small and medium enterprises (SMEs), is hosting Biban24. This significant event, designed to promote entrepreneurship and growth opportunities, brings together global entrepreneurs and investors...

Continue Reading